2012
Adjuvant therapy in stage I carcinoma of the breast
Schwartz GF, Reis‐Fihlo J, Pusztai L, Fentiman IS, Holland R, Bartelink H, Rutgers EJ, Solin LJ, Palazzo J, Committee A. Adjuvant therapy in stage I carcinoma of the breast. Cancer 2012, 118: 2031-2038. PMID: 22392361, DOI: 10.1002/cncr.27431.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyFemaleGene Expression ProfilingHumansNeoplasms, Hormone-DependentPractice Guidelines as TopicConceptsStage I breast cancerI breast cancerBreast cancerAdjuvant therapyConsensus conferenceStage ILymph node-negative breast cancerNode-negative breast cancerKimmel Cancer CenterAdjuvant chemotherapyAdjuvant hormonesAdjuvant treatmentCancer CenterClinical trialsThomas Jefferson UniversityTreatment criteriaTreatment decisionsIndividual tumorsCancerGenetic factorsChemotherapyMolecular phenotypingTherapyHormoneCurrent data
2011
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals Of Surgical Oncology 2011, 19: 1508-1516. PMID: 22193884, DOI: 10.1245/s10434-011-2108-2.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPrimary breast cancerBreast cancerSystemic therapyBreast-conserving surgery rateLarge adjuvant trialsPathologic complete responseInflammatory breast cancerNew therapeutic regimensIntermediate end pointsInternational Consensus ConferenceClinical research groupAdjuvant trialsNew regimensPathologic responseComplete responseSurgery ratesTherapeutic regimensConsensus conferenceEnd pointTherapyCancerTrialsRegimensPanel of representativesProposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
Loi S, Symmans WF, Bartlett J, Fumagalli D, Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. The Lancet Oncology 2011, 12: 1162-1168. PMID: 21684810, DOI: 10.1016/s1470-2045(11)70117-6.Peer-Reviewed Original ResearchConceptsNorth American Breast Cancer GroupBreast International GroupClinical trialsBiopsy procedureNeoadjuvant breast cancer trialsNeoadjuvant clinical trialsBreast cancer clinical trialsBreast cancer groupBreast cancer trialsStart of treatmentCancer clinical trialsNational Cancer InstituteNeoadjuvant trialsDefinitive surgeryNeoadjuvant treatmentCancer groupStudy protocolCancer trialsBreast cancerCancer InstituteUniform collectionTumor tissueBlood collectionTrialsSpecimen types
2009
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine. The Oncologist 2009, 14: 320-368. PMID: 19346299, DOI: 10.1634/theoncologist.2008-0230.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorBreast NeoplasmsEverolimusEvidence-Based MedicineFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ HybridizationLapatinibNeoplasm StagingPolymerase Chain ReactionPractice Guidelines as TopicPrognosisPyrazolesPyrimidinesQuinazolinesReceptor, ErbB-2RNA, MessengerSirolimusSurvival AnalysisTaxoidsTrastuzumabTreatment OutcomeUp-RegulationConceptsBreast cancerOverall survivalInsulin-like growth factor receptor pathwayClinical Oncology-CollegeMetastatic breast cancerInvasive breast cancerAmerican Pathologists guidelinesHER-2 receptorTyrosine kinase inhibitorsTarget of therapyGrowth factor receptor pathwayKinase inhibitor lapatinibMean relative riskReal-time polymerase chain reactionTransmembrane tyrosine kinase receptorPrediction of responseChromosome 17 polysomyHormonal therapyTyrosine kinase receptorsTherapy toxicitySitu hybridizationPrognostic significancePolymerase chain reactionPathologists guidelinesRelative risk